Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Tuesday 08 August 2023 3:26 pm  |  Updated:  Tuesday 08 August 2023 4:40 pm

Tribunal upholds £84m CMA fine for firm that hiked drug prices

By: City PM Reporter

Add as a preferred source on Google

The companies behind a drug whose price was hiked from £20 to £248 per pack in just eight years will be fined a combined £84 million after a tribunal upheld the competition watchdog’s decision.

The Competition Appeal Tribunal on Tuesday had endorsed “all the main elements” of the Competition and Markets Authority’s decision, the CMA said.

However it reduced the overall fine for the three businesses from around £101 million.

The CMA said that the price of a packet of liothyronine tablets had increased by more than 12-fold between 2009 and 2017.

The only supplier of the tablets, used to treat thyroid hormone deficiency, was Advanz.

Advanz is currently owned by Advanz Pharma, but previous owners Cinven and HgCapital also share in the fine.

Advanz Pharma will pay £40.9 million, Cinven £37.1 million and Hg £6.2 million, the tribunal decided.

Cinven declined to comment, Advanz Pharma and Hg have been contacted.

CMA executive director of enforcement Michael Grenfell said: “We are delighted that the Competition Appeal Tribunal has unanimously upheld the CMA’s infringement findings.

Read more

Regulator wins decade-long pricing tussle with Pfizer

Hikma reported a jump in profit for 2024

“Today’s landmark judgment reinforces the need for companies to think carefully about how they set prices and paves the way for the NHS to seek compensation.

“The CMA will continue to crack down on companies which abuse their market power in ways that harm people and the wider economy.”

The CMA said that its finding that Advanz abused its dominant position had been upheld by the tribunal.

It had charged “excessive and unfair prices,” the CMA said.

“In particular, the Tribunal found that the price increases were part of a deliberate strategy to exploit the lack of regulatory or competitive constraints and resulted in a significant impact on the NHS.

“The Tribunal dismissed all of the appellants’ grounds of appeal on liability.

“NHS annual spending on the tablets in 2006, the year before the implementation of the strategy, was £600,000, but by 2009 had increased to more than £2.3 million and jumped to more than £30 million by 2016.”

Press Association –  August Graham

Read more

Ticket reseller StubHub UK fined nearly £1m for hiding fees

Aerial view of Glastonbury Festival showcasing vibrant crowds, colorful tents, and iconic Pyramid Stage under clear skies

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Related Topics

  • Competition and Markets Authority
  • NHS
  • Pharmaceuticals
  • Pharmaceuticals

Trending Articles

  • Burnham told to launch £100bn tax reform package

  • Billionaire Easyjet founder in line for £800m payday from takeover

  • Construction sector cuts jobs again as house building slumps

  • Harry Styles at Wembley Stadium review: running through the grief

  • Tickets for England World Cup quarter vs Norway on sale for $8m

More from City PM

  • Regulator wins decade-long pricing tussle with Pfizer

    Legal
    Hikma reported a jump in profit for 2024
  • Ticket reseller StubHub UK fined nearly £1m for hiding fees

    Retail
    Aerial view of Glastonbury Festival showcasing vibrant crowds, colorful tents, and iconic Pyramid Stage under clear skies
  • Google hit with UK-first AI crackdown over publisher content

    Tech
    Googles modern Kings Cross headquarters showcasing innovative architecture in Londons dynamic tech district
  • Apple claims CMA app store shake-up could ‘open the door to scams’

    Tech
    Apple App Store with UK flag and warning sign about potential scams due to proposed CMA competition reforms
  • ‘Bogus claim’: Ryanair hits back at watchdog probe into family seating policy

    Transport & Infrastructure
    Elon Musk and Ryanair CEO Michael O’Leary face off amid acquisition rumors in a business meeting setting
  • CMA launches antitrust probe into Hollywood’s mega merger

    Media
    GettyImages 2250424721 shows a professional business meeting with diverse executives discussing strategies in a modern con...
  • Ryanair blasts ‘misguided’ watchdog over family seating probe

    Transport & Infrastructure
    Michael OLeary speaking at a Ryanair press conference, dressed in a suit, discussing the airlines latest business updates
  • Associated British Foods toasts approval for £75m Hovis takeover 

    Retail
    Hovis is in talks of a merger with Kingsmill. (Image: Wikimedia Commons)

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy